These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23801551)

  • 1. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs'.
    Yan Z
    Stat Med; 2013 Dec; 32(30):5484-6. PubMed ID: 24302283
    [No Abstract]   [Full Text] [Related]  

  • 3. Authors' reply to Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs".
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5487-8. PubMed ID: 24302284
    [No Abstract]   [Full Text] [Related]  

  • 4. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
    Yu YP; Yan XY; Yao C; Xia JL
    Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing bioequivalence in complete and incomplete data designs using AUCs.
    Jaki T; Wolfsegger MJ; Lawo JP
    J Biopharm Stat; 2010 Jul; 20(4):803-20. PubMed ID: 20496207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing bioequivalence in serial sacrifice designs.
    Wolfsegger MJ
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):103-13. PubMed ID: 17053981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach for sample size determination of average bioequivalence based on interval estimation.
    Chiang C; Hsiao CF
    Stat Med; 2017 Mar; 36(7):1068-1082. PubMed ID: 28070984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence evaluation of sparse sampling pharmacokinetics data using bootstrap resampling method.
    Shen M; Machado SG
    J Biopharm Stat; 2017; 27(2):257-264. PubMed ID: 27906608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
    Chen YI; Huang CS
    Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
    Rasmussen HE; Ma R; Wang JJ
    Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
    [TBL] [Abstract]